X
Xanadu Bio
Pioneering cystic fibrosis treatment through small molecules and gene editing
About Xanadu Bio
Xanadu Bio is at the forefront of medical research, focusing on developing advanced treatments for cystic fibrosis. Co-founded by Dr. Marie Egan and Dr. Akiko Iwasaki, both esteemed professors at Yale University, the company leverages cutting-edge research in molecular biology and immunobiology. Dr. Egan's expertise lies in correcting the CFTR defect in cystic fibrosis through small molecules and gene editing, while Dr. Iwasaki's work focuses on immune defense mechanisms and mucosal vaccine strategies. The company operates in the biotechnology sector, targeting healthcare providers and patients affected by cystic fibrosis. Xanadu Bio's business model revolves around research and development, aiming to monetize through partnerships with pharmaceutical companies and healthcare institutions. The company generates revenue by advancing its proprietary treatments through clinical trials and securing licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Lower Merion Township, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 80.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Genetics and genomics, Spinout, Disease, Biotech and Pharma, AI Drug Discovery, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Sep 2025 | $11M | $44M | Undisclosed | ↗ |
| SPINOUTOther financing | Jan 2021 | $0 | — | Yale University | — |
Growth signals
Latest recorded traffic for Xanadu Bio is 330 monthly website visits, down 59.8% over the last three months. Xanadu Bio's team grew 28.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors2 additional known investors
Yale University
Yale Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Xanadu Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Xanadu Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.